Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis

Barbara Segal, Nelson L. Rhodus, Ketan Patel

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by inflammation involving large and small joints. Systemic manifestations as well as involvement of paraoral tissues contribute to morbidity. Tumor necrosis factor (TNF) plays a central role in RA by amplifying inflammation in multiple pathways that lead to joint destruction. Tumor necrosis factor inhibitors were first licensed for clinical use in 1998; 3 have been approved for the treatment of RA: Iinfliximab, etanercept, and adalimumab. The purpose of this paper is to review the pathogenesis of RA, the state of the art of therapy, and the most current information on the safety and efficacy of TNF inhibitors for treatment of RA.

Original languageEnglish (US)
Pages (from-to)778-787
Number of pages10
JournalOral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology
Issue number6
StatePublished - Dec 2008


Dive into the research topics of 'Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this